Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Oct, 30 2025 that its board has approved proposed amendments to the company’s Articles of Association and will apply for corresponding changes in industrial and commercial registration records.

The key change is the planned abolition of the Supervisory Committee, with its statutory oversight responsibilities to be assumed by the Board-level Audit Committee. The revision aligns the company’s governance framework with the amended PRC Company Law that took effect on Jul, 1 2024 and new guidelines issued by the China Securities Regulatory Commission in Mar, 2025.

The amendments, collectively termed the “2025 Proposed AOA Amendments,” will be put to a vote at the company’s second extraordinary general meeting in 2025, where they must secure at least two-thirds of shareholder votes to take effect.

Should shareholders approve, the Supervisory Committee will be dissolved, current supervisors will step down, and the Audit Committee will formally take over all supervisory duties. Related supervisory procedures and rules will be revoked simultaneously. Until the amendments are adopted, the existing Supervisory Committee will continue to operate under current regulations.

The board stated that the changes are intended to streamline oversight functions and ensure full compliance with evolving regulatory requirements in China.